Regulus Therapeutics (RGLS) Insider Trading & Ownership $8.16 0.00 (0.00%) As of 06/25/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Regulus Therapeutics (NASDAQ:RGLS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.35%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$178.45KNumber OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$282.24K Get RGLS Insider Trade Alerts Want to know when executives and insiders are buying or selling Regulus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address RGLS Insider Buying and Selling by Quarter Regulus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/3/2025Preston KlassenInsiderBuy12,000$7.99$95,880.00 1/30/2025David BaltimoreDirectorBuy19,610$1.06$20,786.60 1/30/2025Joseph P HaganCEOBuy50,000$1.09$54,500.00 1/13/2025Christopher Ray AkerVPSell38,547$1.26$48,569.22 1/13/2025Crispina CalsadaCFOSell38,716$1.26$48,782.16 1/13/2025Joseph P HaganCEOSell115,290$1.26$145,265.40 1/13/2025Preston KlassenInsiderSell31,445$1.26$39,620.70 7/25/2024Kathryn J CollierDirectorBuy4,000$1.82$7,280.00 (Data available from 1/1/2013 forward) RGLS Insider Trading Activity - Frequently Asked Questions Who is on Regulus Therapeutics' Insider Roster? The list of insiders at Regulus Therapeutics includes Christopher Ray Aker, Crispina Calsada, David Baltimore, Joseph P Hagan, Kathryn J Collier, and Preston Klassen. Learn more on insiders at RGLS. What percentage of Regulus Therapeutics stock is owned by insiders? 4.35% of Regulus Therapeutics stock is owned by insiders. Learn more on RGLS's insider holdings. Which Regulus Therapeutics insiders have been buying company stock? The following insiders have purchased RGLS shares in the last 24 months: David Baltimore ($20,786.60), Joseph P Hagan ($54,500.00), Kathryn J Collier ($7,280.00), and Preston Klassen ($95,880.00). How much insider buying is happening at Regulus Therapeutics? Insiders have purchased a total of 85,610 RGLS shares in the last 24 months for a total of $178,446.60 bought. Which Regulus Therapeutics insiders have been selling company stock? The following insiders have sold RGLS shares in the last 24 months: Christopher Ray Aker ($48,569.22), Crispina Calsada ($55,289.08), Joseph P Hagan ($162,615.60), and Preston Klassen ($39,620.70). How much insider selling is happening at Regulus Therapeutics? Insiders have sold a total of 244,046 Regulus Therapeutics shares in the last 24 months for a total of $306,094.60 sold. More Insider Trading Tools from MarketBeat Related Companies BioCryst Pharmaceuticals Insider Trades Amicus Therapeutics Insider Trades Celldex Therapeutics Insider Trades Innoviva Insider Trades Dynavax Technologies Insider Trades MannKind Insider Trades Novavax Insider Trades OPKO Health Insider Trades Geron Insider Trades Myriad Genetics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:RGLS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
